Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1459
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis ; volume:263 ; number:2 ; day:8 ; month:12 ; year:2015 ; pages:354-360 ; date:2.2016
Journal of neurology ; 263, Heft 2 (8.12.2015), 354-360, 2.2016
- Keyword
-
Hirnkrankheit
Neuropsychiatrie
Nervenkrankheit
- Creator
-
Kappos, Ludwig
- Contributor
-
Radue, Ernst-Wilhelm
Chin, Peter
Ritter, Shannon
Tomic, Davorka
Lublin, Fred
SpringerLink (Online service)
- DOI
-
10.1007/s00415-015-7978-y
- URN
-
urn:nbn:de:1111-2018032220770
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kappos, Ludwig
- Radue, Ernst-Wilhelm
- Chin, Peter
- Ritter, Shannon
- Tomic, Davorka
- Lublin, Fred
- SpringerLink (Online service)
Other Objects (12)
Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
Prediction of prognosis and response to fingolimod in people with relapsing-remitting multiple sclerosis
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Fingolimod initiation in multiple sclerosis patients is associated with potential beneficial cardiovascular autonomic effects
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod
REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal
Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension
Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
Prediction of prognosis and response to fingolimod in people with relapsing-remitting multiple sclerosis
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Fingolimod initiation in multiple sclerosis patients is associated with potential beneficial cardiovascular autonomic effects
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod
REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal
Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension
Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
Prediction of prognosis and response to fingolimod in people with relapsing-remitting multiple sclerosis
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Fingolimod initiation in multiple sclerosis patients is associated with potential beneficial cardiovascular autonomic effects
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod
REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal
Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis